Friday, October 10

(The presenters of gray titles did not allow the online appearance of their lectures )

70. INVASION AND METASTASIS

ROOM A, 08.00-12.00 – Friday, October 10

Chair Persons: Y.G. Man, K. Nakamura

A novel hypothesis for tumor invasion and metastasis. Y.G. Man, I. Avital, A. Stojadinovic (Richmond, VA, USA) (30’)
Effects of inflammatory stimulation on programmed cell death 4 expression and invasive activity in human colorectal carcinoma cells. K. Nakamura, S. Sasaki, M. Hatai, S. Kagota, K. Shinozuka, N. Yoshikawa (Nishinomiya, Hyogo, Japan) (15’)
WAP-T mice: A preclinical mouse model to study mammary carcinogenesis, progression, and metastasis. F. Wegwitz, E. Lenfert, C. Mänz, G. Tolstonog, W. Deppert (Hamburg; Göttingen, Germany; Lausanne, Switzerland) (30’)
Pathobiological pathways with clinical significance involved in hepatic metastases from colorectal cancer -recent advances. K.A. Paschos, A.W. Majeed, N.C. Bird (Sheffield, UK) (20’)
A choelsterol lowering drug prevents osteolyitc bone metastasis by targeting osteoclastogenic factors in bone microenvironment. C.C. Mandal (Ajmer, Rajasthan, India) (15’)
The progression of breast cancer is associated with decrease of level of new ARP2/3 inhibitor arpin. M.E. Lomakina, R. Gorelik, I. Dang, V.D. Ermilova, A. Gautreau, A.Y. Alexandrova (Moscow, Russia; Gif-sur-Yvette, France) (20’)
Genetic factors involved in human colorectal cancer metastasis. O. Bajenova, S.J. O’Brien (St. Petersburg, Russia) (20’)

71. INVASION AND METASTASIS

ROOM A, 13.00-16.00 Friday, October 10

Chair Persons: A.Z. Dudek, M. Schauer

Transcription factor FoxM1 and tumor suppressor ARF effect on melanoma tumor angiogenesis and metastases. A.Z. Dudek, K. Terai (Chicago, IL, USA) (30’)
Heparin attenuates melanoma metastasis by interference with binding and signaling function of the integrin VLA-4. M. Schlesinger, U. Gerber, P. Schmitz, L. Borsig, G. Bendas (Bonn, Germany; Zurich, Switzerland) (30’)
Increased circulation of galectin-3 in cancer patients is an important metastasis promoter and attractive therapeutic target. L-G Yu (Liverpool, UK) (30’)
Genome-wide analysis targeting focal adhesion signaling in metastatic breast cancer and early translation for therapeutic applications. M.A. Alaoui-Jamali (Montreal, QC, Canada) (30’)
Bone metastases in renal cell carcinoma are promoted by Calcium via calcium sensing receptor signaling. W. Brenner, E.Jöckel, T. Haber, F.C. Roos, D. Prawitt, K. Junker, C. Hampel, J.W. Thüroff (Mainz; Hombur/Saar, Germany) (15’)
In vitro modelling of colorectal cancer cell arrest in the hepatic sinusoids: cancer cell interactions with kupffer cells and sinusoidal endothelial cells in colorectal cancer liver metastasis. K.A. Paschos, A.W. Majeed, N.C. Bird (Sheffield, UK) (15’)

72. ADVANCES IN GYNECOLOGICAL CANCER

ROOM B, 8.00-12.00 – Friday, October 10

Chair Persons: R. Ganapathi, D. Kieback

Gene expression profiling of ovarian cancer: Are we making progress? R. Ganapathi, J. Sehouli, I. E. Braicu and M. Ganapathi (Charlotte, NC, USA; Berlin, Germany) (15’)
Next generation expression profiling of primary and recurrent ovarian tumors. M. K. Ganapathi, W. Jones, J. Sehouli, C. M. Michener, I. E. Braicu, C. Biscotti, S. A.J. Vaziri and R. N. Ganapathi (Charlotte; Durham, NC; Cleveland, OH, USA; Berlin, Germany) (15’)
The main principles of treatment for the early stage borderline ovarian tumors in women of reproductive age. I.N. Pinchuk , M.A. Liushnenko (Surgut, Russia) (10’)
Could HE4 help in decision-making in relation to the individualization of the extent of surgical staging in patients with endometrial cancer. J. Presl, Z. Novotny, O. Topolcan, P. Vlasak, R. Kucera, R. Fuchsova, J. Vrzalova and L. Betincova (Pilen, Czech Republic) (15’)
Breast cancer risk prediction: A journey from accurate information on breast cancer diagnosis, to epidemiology and biomarkers. E.O. Fourkala (London, UK) (20’)
Modeling for a comprehensive tissue-based repository supporting translational discoveries in ovarian cancer. D. Bassiouny, M. Naeim, S. Nofech-Mozes, N. Ismiil, V. Dubé, G. Han, M. Cesari, E. Slodkowska, F-I. Lu, S. Salama, H.F.Chiu, M.A. Khalifa (Toronto, ON, Canada) (15’)
Microcirculation in patients with gynecological cancer. I. Tikhomirova, D. Lileev, N. Kislov, I. Gordeev, M. Schekaleva (Yaroslavl, Russia) (10’)
E-cadherin -160 C/A genetic polymorphism and cervical intraepithelial neoplasia. I.C. Rotar, D. Mursan, F. Petrisor, P. Radu, P. Cotutiu, F. Stamatian (Cluj Napoca, Romania) (15′)
Borderline ovarian tumors – are they benign or malignant? A. Lazarou, C. Fotopoulou, A. Coumbos, J. Sehouli, J. Vasiljeva, I. Braicu, H. Burger, W. Kuehn (Berlin, Germany) (20’)

73. ADVANCES IN HEAD AND NECK CANCER

ROOM B, 13.00-15.30 – Friday, October 10

Chair Person: S. Syrjänen, K. Syrjänen

Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. N. Murakami, S. Yoshimoto, F. Matsumoto, T. Ueno, Y. Ito, K. Kobayashi, K. Harada, M. Kitaguchi, S. Sekii, K. Takahashi, K. Yoshio, K. Inaba, M. Morota, M. Sumi, Y. Saito, J. Itami (Tokyo, Japan) (15’)
Natural history of HPV in head and neck region- where are we now? S. Syrjänen (Turku, Finland) (40’)
Potentiation of cetuximab by inhibition of tregs in metastatic squamous cell cancers of head and neck. G.L. Jha, J.S. Miller (Minneapolis, MN, USA) (20’)
Runx genes – promising biomarkers for metastatic spread in oropharyngeal carcinomas. P. Papagerakis, Y. Seon, L. Zheng, M.A. Sartor, Y. Zhang, E. Bellile, B. Li, M. Matossian, M. Pliakas, O. Shkeir, J. McHugh, G. Pannone, D. Chepeha, G. Wolf, C. Ge, R.T. Franceschi, S. Papagerakis (Ann Arbor, MI, USA; Foggia, Italy) (30’)
Clinical Significance of Kallikrein-related-peptidase-4 in Oral Cancer. P. Papagerakis, G. Pannone, M. Athanassiou-Papaefthymiou, Y. Yamakoshi, S. McGuff, O. Shkeir, K. Ghirtis, S. Papagerakis (Ann Arbor, MI; San Antonio, TX, USA; Foggia, Italy) (20’)

74. TUMOR ANGIOGENESIS AND ANTI- ANGIOGENESIS

ROOM C, 08.00-12.00 – Friday, October 10

Chair Persons: S. Kumar, W.G. Jiang, G. Sica

Anti-angiogenesis: targeting cd105 in cancer patients-what next? W.H. Fang, P. Kumar, S. Kumar (Manchester, UK) (20′)
Glioblastoma cancer stem cells and angiogenesis. A. Colabianchi, G. Lama, A. D’Alessio, G. Proietti, C. Angelucci, A. Mangiola, G. Maira, E. Binda, A. Vescovi, G. Sica (Rome; Milan, Italy) (15′)
New and alternative approaches in targeting angiogenesis and metastasis. W.G. Jiang (Cardiff, UK) (30′)
mTOR/PI3k/Akt signaling pathway in tumor angiogenesis and therapeutic targeting. P. Mabeta, P.F. Davis, M.S. Pepper (Thswane, South Africa; Wellington, New Zealand) (15′)
Expression of angiogenesis-related factors in glioblastoma and peritumor tissue. G. Lama, A. Colabianchi, G. Proietti, A. Mangiola, F. Biamonte, G. Maira, G. Sica (Rome, Italy) (15′)
Regulation of angiogenesis by WNT signalling in non-small cell lung cancers. V. Sarosi, J. Rapp, T. Kovacs, D. Feller, G. Smuk, J.E. Pongracz (Pecs, Hungary) (30′)
Three dimensional in vitro models for studying cancer angiogenesis. L. Bray (Dresden, Germany) (10′)
Effects of a mast cell stabilizer on the vascularization of mammary tumors: Ultrasonographic evaluation. A.I.Faustino-Rocha, A. Gama, M.J. Pires, P.A. Oliveira, M. Ginja (Vila Real, Portugal) (15′)

75. MELANOMA: NEW THERAPIES AND BIOMARKERS

ROOM C, 13.00-15.30 – Friday, October 10

Chair Persons: F.J. Lejeune, O. Zoras

New Achilles heels in melanoma? F.J. Lejeune (Lausanne, Switzerland) (20′)
Isolated limb perfusion with TNFa and melfalan for unresectable melanoma and soft tissue sarcoma. O. Zoras (Heraclion, Greece) (30’)
Prognostic value of perioperative assessment of circulating melanoma cells in hyperthermic isolated limb perfusion: interim results. D. Michelakis, I. Messaritakis, K. Lasithiotakis, H. Ioannou, I. Souglakos, D. Stamatiou, O. Zoras (Heraklion, Greece; York, UK) (10′)
Comparative metabolomics of primary and metastatic melanoma cells – towards novel diagnostic method. G.K. Ramachandran (Singapore, Singapore) (15′)

76. ADVANCES IN BREAST CANCER

ROOM D, 08.00-12.00 – Friday, October 10

Chair Persons: P.A. Townsend, S. Kraemer

Annexin A3 is a breast cancer marker secreted by neoplastic cell lines and involved in cell migration. B.A. Zeidan, T. Jackson, S.E.T. Larkin, R.I. Cutress, G.R. Coulton, M. Ashton-Key, N. Murray, H.E. Johnston, G. Packham, S.D. Garbis, P.A. Townsend (Southampton; London; Manchester, UK) (30′)
Local breast cancer treatment with targeted oncoplastic breast surgery. S. Kraemer, W. Malter, V. Kirn, K. Rogee, L. Richters, P. Mallmann (Cologne, Germany) (20′)
New strategies to overcome endocrine resistance in metastatic breast cancer. S. Kraemer, M. Wirtz, V. Kirn, L. Richters, J. Puppe, A. Ulhaas, K. Rogee, W. Malter, P. Mallmann (Cologne, Germany) (20′)
Primary breast cancer and corresponding axilary lymph node metastases: do they have the same molecular profile? M. Raica (Timisoara, Romania) (30′)
Estrogen blockade and tailored chemotherapy in high risk premenopausal breast cancer (BC). F. Recchia, S. Necozione, M. Bratta, S. Rea (Avezzano; Rome; L’Aquila, Italy) (15′)
Lymphangiogenesis in molecular types of breast cancer. A.M. Cimpean, M. Raica (Timisoara, Romania) (20′)
Polymorphisms in CYP19A1 gene predicts relapse and survival in postmenopausal breast cancer patients treated with adjuvant letrozole. G. Umamaheswaran, D. Kadambari, B. Dubashi, K.R. Reddy, C. Adithan, S.A. Dkhar (Pondicherry, India) (15′)

77. ADVANCES IN HEMATO-ONCOLOGY

ROOM D, 13.00-16.00 – Friday, October 10

Chair Persons: A. Polliack, V. Barak, T. Tadmor

Recent advances in management of CML. B. Shah (Lewiston, ID, USA) (30′)
Thymidine Kinase (TK) levels can discriminate patients with a Low to High Grade Lymphoma transformation. V. Barak, N. Goldschmidt, I. Kalichman, M.E. Gatt (Jerusalem, Israel) (30′)
Richter syndrome in chronic lymphocytic leukemia: A retrospective study reporting clinical data and outcome from the Israeli CLL Study Group. T. Tadmor, L. Shvidel, O. Bairey, N. Goldschmidt, R. Ruchlemer, R. Fineman, N. Rahimi-Levene, Y. Herishanu, M. Yuklea, A. Arad, A. Aviv, A. Polliack (Tel Aviv; Jerusalem; Haifa; Kfar Saba; Natanya, Israel) (30′)
Therapeutic potential of targeting sphingosine kinases in T-cell acute lymphoblastic leukemia. C. Evangelisti (Bologna, Italy) (30′)

78. MICRORNAS IN CANCER

ROOM E, 09.00-11.00 – Friday, October 10

Chair Persons: F. Pentimalli, A. Seth

Targeting malignant mesothelioma: multiple approaches are required. F. Pentimalli, L. Esposito, I.M. Forte, D. Di Marzo, C.A. Iannuzzi, P. Indovina, A. Giordano (Naples; Siena, Italy; Philadelphia, PA, USA) (30’)
Aberrant miR-182 expression enhances the metastatic potential of prostate cancer and is associated with clinical recurrence. A. Gordanpour, Y. Amemiya, R. Nam, J. Bendavid, L. Sugar, A. Seth (Toronto,ON, Canada) (15’)
Epigenetics and regulatory microRNAs in the development and control of tumor. K.P. Gupta, P. Tiwari (Lucknow, India) (30’)
MiRNA expression profiling of locally advanced breast cancer (LABC) during neo-adjuvant chemotherapy (NAC) M. Al-Khanbashi, S. Caramuta, A. Al-Ajmi, I. Al-Haddabi, L.Weng-Onn, M. Al-Moundhri (Solna, Sweden) (10’)

79. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B.A. Littlefield

ROOM F, 09.00-12.30 – Friday, October 10

Chair Persons: M. Postema, J. De Brabander

Development of eribulin, a macrocyclic ketone analog of halichondrin B, for advanced breast cancer. B.A. Littlefield (Andover, MA, USA) (40′)
Karlotoxins exhibit a unique mechanism for the control of cancer cells. M.T. Hamann (Oxford, MS, USA) (20′)
Antiproliferative and proapoptotic actions of highly purified betanin extracted from Beta vulgaris on MCF-7 cancer cells. L. Nowacki, P. Vigneron, F. Merlier, L. Rotellini, R. Ralanairina, J.-P. Gadonna, C. Rossi, M. Vayssade (Compiègne; Beauvais, France) (15′)
Cancer drug discovery from fragments to marine natural products. R. Li (Omaha, NE, USA) (25′)
Anticancer drug discovery based on plant biodiversity. H. Zhang, K. Liu, Y.Guan (Kowloon, Hong Kong) (10′)
Essential oil extracted from the resin of Pistacia lentiscus var chia (mastic oil): Antitumor efficacy against colorectal cancer. K. Spyridopoulou, A. Tiptiri-Kourpeti, E. Fitsiou, S. Vaseiliadis, H. Bardouki, A. Galanis, A. Pappa, K. Chlichlia (Alexandroupolis; Athens, Greece) (10′)